Home
Home

Prolor

Revisiting Buyout Rumors After Teva's CEO Shifts Focus To 'Smaller Acquisitions'

Revisiting Buyout Rumors After Teva's CEO Shifts Focus To 'Smaller Acquisitions'
Seeking Alpha

Prolor Biotech Is Worth An Investor's Research

Prolor Biotech Is Worth An Investor's Research
Seeking Alpha

Prolor Biotech: A Good Leadership Team That Can Make A Company Profitable

Prolor Biotech: A Good Leadership Team That Can Make A Company Profitable
Seeking Alpha

Prolor Biotech Receives A Boost On Data Presentation

Prolor Biotech Receives A Boost On Data Presentation
Seeking Alpha

Noteworthy Insider Buys Last Week In 2 Beaten Down Biotechs, With 4 Other Buys And Sells

Noteworthy Insider Buys Last Week In 2 Beaten Down Biotechs, With 4 Other Buys And Sells
Seeking Alpha

PROLOR Biotech Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders

PROLOR Biotech Receives Letter from NYSE Amex Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
Yahoo/PR NewsWire

Prolor Biotech's Phase II Initiation Has Profound Pipeline Implications

Prolor Biotech's Phase II Initiation Has Profound Pipeline Implications
Seeking Alpha

President Of Prolor Biotech Bullish About His Firm's Pipeline And Positioning

President Of Prolor Biotech Bullish About His Firm's Pipeline And Positioning
Seeking Alpha

Medgenics' Disruptive Biotechnology Is One To Watch

Medgenics' Disruptive Biotechnology Is One To Watch
Seeking Alpha

2 Biotechs On Teva's Radar Screen

2 Biotechs On Teva's Radar Screen
Seeking Alpha